PDCD1 and neoplasm: Anti-CTLA-4 and anti-PD-1/PD-L1 treatment exhibited a potent and durable tumor-killing effect in multiple advanced cancers such as triple-negative breast cancer, non-small lung cancer, renal cell cancer, melanoma, and urothelial bladder cancer [77–81].